Premium
CLINICAL STUDY OF THE USE OF THE NEW AMINOGLYCOSIDE TOBRAMYCIN FOR THERAPY OF INFECTIONS DUE TO GRAM‐NEGATIVE BACTERIA
Author(s) -
Meyers Burt R.
Publication year - 1977
Publication title -
medical journal of australia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 131
eISSN - 1326-5377
pISSN - 0025-729X
DOI - 10.5694/j.1326-5377.1977.tb113918.x
Subject(s) - tobramycin , enterobacter cloacae , medicine , aminoglycoside , microbiology and biotechnology , superinfection , serratia marcescens , enterobacter , staphylococcus aureus , klebsiella pneumoniae , antimicrobial , antibiotics , cellulitis , pseudomonas aeruginosa , gentamicin , escherichia coli , biology , immunology , bacteria , biochemistry , virus , genetics , gene
Tobramycin, a new aminoglycoside antimicrobial, was evaluated as therapy for infections due to Gram‐negative bacilli in 15 seriously ill patients with underlying diseases. Three of 10 patients with Gram‐negative bacteraemia also had a urinary tract infection. Two patients had a respiratory tract infection, one had cellulitis, one had a urinary tract infection, and another had septic phlebitis. Twelve patients were cured of their infections. Eosinophilia was observed in one patient, and another developed superinfection with Staphylococcus aureus after 6 days of tobramycin therapy. There were five isolates of Escherichia coli , five of Klebsiella sp., two of Pseudomonas sp., and one each of Enterobacter agglomerans, Serratia marcescens and Enterobacter cloacae . The average serum concentration of tobramycin 2 hr after a parenteral dose of 1·0 to 1·5 mg/kg was 5·1 μg/ml; higher concentrations of tobramycin were present in urine. Tobramycin proved to be an effective antimicrobial in these patients.